ALK and non-small cell lung carcinoma: In the past few decades, with the continuous deepening of knowledge of molecular mechanisms, drugs targeting EGFR, ALK, PD-1/PD-L1 have profoundly changed the treatment strategy of non-small cell lung cancer (NSCLC) [4, 5].